M&A Deal Summary

Agennix AG Acquires GPC Biotech

On November 5, 2009, Agennix AG acquired life science company GPC Biotech

Acquisition Highlights
  • This is Agennix AG’s 1st transaction in the Life Science sector.
  • This is Agennix AG’s 1st transaction in the United States.
  • This is Agennix AG’s 1st transaction in New Jersey.

M&A Deal Summary
Date 2009-11-05
Target GPC Biotech
Sector Life Science
Buyer(s) Agennix AG
Deal Type Add-on Acquisition

Target

GPC Biotech

Princeton, New Jersey, United States
GPC Biotech is a mechanism-based drug discovery and development company focused on treatments for cancer and fungal infections.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Agennix AG

Heidelberg, Germany
Category Company
Sector Life Science
Employees52
DESCRIPTION

Agennix AG is a biopharmaceutical company. The Company’s clinical development programs include oral talactoferrin alfa; a topical gel form of talactoferrin and RGB-286638, a multi-targeted kinase inhibitor.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (New Jersey) 1 of 1
Country (United States) 1 of 1
Year (2009) 1 of 1
Mergr

Product

Company

Legal